TPST-1495
Advanced Solid Tumors (e.g., colorectal cancer, FAP)
Phase 1Active
Key Facts
Indication
Advanced Solid Tumors (e.g., colorectal cancer, FAP)
Phase
Phase 1
Status
Active
Company
About Tempest Therapeutics
Tempest Therapeutics is advancing a novel oncology pipeline focused on overcoming resistance to immunotherapy by targeting tumor-intrinsic and immune-mediated pathways. Its lead candidate, TPST-1120, is in a global randomized Phase 1b/2 trial in combination with standard-of-care for frontline liver cancers, with recent data showing promising survival signals. The company's strategy is to develop oral, targeted agents that can be used as monotherapies or in combinations to improve outcomes for patients with advanced solid tumors. Despite a challenging financial position, Tempest is executing on key clinical readouts and pursuing strategic partnerships to advance its programs.
View full company profile